Team:Imperial College London

From 2009.igem.org

(Difference between revisions)
 
(242 intermediate revisions not shown)
Line 1: Line 1:
-
{{Imperial/09/CSS}}
+
{{Imperial/09/TemplateTop}}
-
<html>
+
[[Image:II09_Encapsi2.png|The E.ncapsulator text|725px]]
-
<body>
+
<br>
-
<!--<div id="II09_mainWrapper">-->
+
[[Image:II09_Logo_Hello.gif|left|The E.ncapsulator|320px]]
-
</html>
+
For iGEM 2009 the Imperial College London team present you with <b><i>The E.ncapsulator</i></b>; a versatile manufacturing and delivery platform by which therapeutics can be reliably targeted to the intestine.
-
{{Imperial/09/Banner}}
+
<html><a href="https://2009.igem.org/Team:Imperial_College_London/Project_Overview"><img width=150px src="http://i691.photobucket.com/albums/vv271/dk806/ProjectOverviewR.jpg"></a></html><br>
-
{{Imperial/09/Breadcrumb}}
+
Our <i>E.coli</i> chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, protective encapsulation and genome deletion. The temporal transition between each of these stages is controlled by physical and chemical methods, showing a clear engineering approach to tackle this problem.
-
{{Imperial/09/Menu}}
+
-
<html>
+
 +
<b><i>The E.ncapsulator</i></b> provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. <b><i>The E.ncapsulator</i></b> is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology.
 +
<br><br>
 +
<html><center></html>{{Imperial/09/Overview}}<html></center></html>
 +
<br><br>
-
<div id="II09_content_wrapper">
+
<html><hr>
-
<img src="https://static.igem.org/mediawiki/2008/a/a1/Tudelft_content_top.png" width="572">
+
<table border="0"><tr><center><b>Pushed for time? Browse through the main pages using our thumbs below.    Else, take our tour by clicking on these arrows or using the links at the top right of the page</b></center></tr>
-
<div id="II09_content">
+
<tr><td width="20%"><center><a href="https://2009.igem.org/Team:Imperial_College_London/Major_results"><img style="vertical-align:bottom;" width="100%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage2.png"><br><b>Major Results</b></a></center></td>
 +
<td width="20%"><center><a href="https://2009.igem.org/Team:Imperial_College_London/Wetlab/BioBricks"><img style="vertical-align:bottom;" width="100%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage3.png"><br><b>Submitted Parts</b></a></center></td>
 +
<td width="20%" style="border-right:1px solid #000;"><center><a href="https://2009.igem.org/Team:Imperial_College_London/Achievements"><img style="vertical-align:bottom;" width="100%" src="http://i691.photobucket.com/albums/vv271/dk806/II09_Homepageimage4.png"><br><b>Achievements</b></a></center></td>
 +
<td width="20%" style="padding:10px;"><center><a href="https://2009.igem.org/Team:Imperial_College_London/Project_Overview"><img width=150px src="http://i691.photobucket.com/albums/vv271/dk806/ProjectOverviewR.jpg"></a></center></td>
 +
</tr>
 +
</table>
</html>
</html>
-
 
+
{{Imperial/09/TemplateBottom}}
-
<!--**************** PUT YOUR CONTENT BELOW (WIKI CODE WORKS)**************** -->
+
-
 
+
-
[[Image:II09_Encapsulator.png|center|The E.ncapsulator|400px]]
+
-
===Creating ‘The E.ncapsulator’: in situ manufacture and oral delivery of human biopharmaceuticals===
+
-
 
+
-
A major, yet unsolved, challenge in the pharmaceutical industry involves overcoming the harsh acidic environment of the stomach in order to deliver proteins to the gut. This year the Imperial College iGEM team has decided to tackle this problem by developing an innovative, self-contained drug fabrication and delivery system. In our 'E.ncapsulator', Escherichia coli will be engineered not only to efficiently manufacure important biopharmaceuticals, but also to coat and protect protein based drugs until release in the small intestine.
+
-
 
+
-
 
+
-
Furthermore, in order to create E.ncapsulator tablets for oral delivery, there has been much focus on designing and engineering a number of modules for implementation in <i>E.coli</i>. The modularity that is central to our project will be evident in the areas of protein drug production, self-encapsulation and genomic neutralisation. Utilising the <i>E.coli</i> bacterium, we are creating a re-usable chassis that will allow the development of a range of biopharmaceuticals to be delivered to the gut. Our E.ncapsulator is therefore intended as an elegant solution to, not one, but a range of human ailments and conditions, which cannot currently be successfully treated by oral drugs.<br>
+
-
 
+
-
 
+
-
The first module involves engineering <i>E.coli</i> to synthesise the protein drug of interest to a tuneable threshold. Once accomplished, activation of module two initiates the encapsulation phase, in which <i>E.coli</i> coats itself in a protective layer of colanic acid to form the E.ncapsulator. This protective capsule is what shields the biopharmaceutical against the harsh acidic environment of the stomach. The third module, genomic neutralisation, is composed of a ‘suicide trigger’ mechanism that destroys the genetic material of the bacteria. Finally, once in the small intestine, the capsule will be degraded, thereby releasing the designed biopharmaceutical to the gut micro biota where it can carry out its intended function.<br>
+
-
 
+
-
 
+
-
The self-encapsulation of a synthetic biology chassis is new to iGEM and represents a completely novel and innovative approach to biopharmaceutical design, manufacture and delivery. Throughout the project we have followed an engineering approach that incorporates modular design, detailed modelling and simulation as well as systematic integration. Using such an approach, we are hopeful that the E.ncapsulator will be coming soon to a Pharmacy near you!<br>
+
-
 
+
-
<!-- **************** CONTENT FINISHES HERE **************** -->
+
-
 
+
-
<html>
+
-
</div>
+
-
<img src="https://static.igem.org/mediawiki/2008/8/89/Tudelft_content_bottom.png" width="572">
+
-
</div>
+
-
 
+
-
<!--</div>-->
+
-
</body>
+
-
</html>
+
-
 
+
-
{{Imperial/09/Footer}}
+

Latest revision as of 02:34, 22 October 2009

The E.ncapsulator text

The E.ncapsulator

For iGEM 2009 the Imperial College London team present you with The E.ncapsulator; a versatile manufacturing and delivery platform by which therapeutics can be reliably targeted to the intestine.
Our E.coli chassis progresses through a series of defined stages culminating in the production of a safe, inanimate pill. This sequential process involves drug production, protective encapsulation and genome deletion. The temporal transition between each of these stages is controlled by physical and chemical methods, showing a clear engineering approach to tackle this problem.

The E.ncapsulator provides an innovative method to deliver any biologically synthesisable compound and bypasses the need for expensive storage, packaging and purification processes. The E.ncapsulator is an attractive candidate for commercial pill development and demonstrates the massive manufacturing potential in Synthetic Biology.

Growth
Growth
The cells are grown to a critical cell density, before the system is started. It allows the culture to reach a sufficient cell number before the the cells are triggered to begin protein production. This is because protein production can slow cell growth.
Module 1: Protein Production
Module 1: Protein Production
The first module is induced with IPTG, which triggers the production of the protein of interest. As part of this project we have looked into two proteins and a peptide of interest.
Module 2: Encapsulation
Module 2: Encapsulation
The second module is where the cell, after having produced the peptide of interest, produces colanic acid. This creates a protecting layer around teh bacterium to shelter it from the acidity of the stomach.
Module 3: Genome deletion
Module 3: Genome deletion
Module 3 occurs after encapsulation of the cell containing the produced peptide of interest. This module makes the bacterium non-viable. It does so by over-expressing restriction enzymes which subsequently cleave the genomic DNA into small fragments. The cell is thus unable to produce any proteins and therefore unable to survive.
Secondary Encapsulation
Secondary Encapsulation
Several manufacturing considerations regarding the post-processing of the culture have been investigated. Post-processing of the culture allows the polypeptide filled cells to be converted into a pharmaceutical tablet, that can be taken orally.
Chemoinduction
Module Integration: Chemoinduction
Module 1 is induced by the addition of a compound, IPTG. This allows the user to 'kickstart' the system once the culture has reached a sufficiently high cell density.
Autoinduction
Module Integration: Autoinduction
Module 2 is triggered by a switch from glucose consumption to a secondary carbon source consumption. When the initial preferential carbon source (glucose) is exhausted, the system will metabolise the secondary carbon source that is available. This switch triggers the promoter that controls the start of Module 2. By knowing the initial concentrations of each carbon source, this acts as a programmable time delay system for the activation of encapsulation.
Thermoinduction
Module Integration: Thermoinduction
Module 3 is initiated upon an increase in temperature. The system is initially grown at 28°C, at which point Module 3 is repressed. When the temperature is raised to 42°C, this repression is blocked, triggering the start of Module 3. This temperature sensitive system was chosen as after encapsulation, chemical induction may be less effective due to limited diffusion.


Pushed for time? Browse through the main pages using our thumbs below. Else, take our tour by clicking on these arrows or using the links at the top right of the page

Major Results

Submitted Parts

Achievements
Mr. Gene   Geneart   Clontech   Giant Microbes

Retrieved from "http://2009.igem.org/Team:Imperial_College_London"